JP7669291B2 - Ａｃｔｒｉｉ結合性タンパク質及びその使用 - Google Patents

Ａｃｔｒｉｉ結合性タンパク質及びその使用 Download PDF

Info

Publication number
JP7669291B2
JP7669291B2 JP2021570756A JP2021570756A JP7669291B2 JP 7669291 B2 JP7669291 B2 JP 7669291B2 JP 2021570756 A JP2021570756 A JP 2021570756A JP 2021570756 A JP2021570756 A JP 2021570756A JP 7669291 B2 JP7669291 B2 JP 7669291B2
Authority
JP
Japan
Prior art keywords
actrii
binding protein
actriib
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021570756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534966A (ja
JPWO2020243448A5 (enExample
Inventor
クマール，ラビンドラ
ベルク，ジョナサン
グリンバーグ，アシャ
サコ，ダイアン
カストングアイ，ロゼリン
Original Assignee
アクセレロン ファーマ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセレロン ファーマ インコーポレーテッド filed Critical アクセレロン ファーマ インコーポレーテッド
Publication of JP2022534966A publication Critical patent/JP2022534966A/ja
Publication of JPWO2020243448A5 publication Critical patent/JPWO2020243448A5/ja
Priority to JP2025067310A priority Critical patent/JP2025118664A/ja
Application granted granted Critical
Publication of JP7669291B2 publication Critical patent/JP7669291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021570756A 2019-05-30 2020-05-29 Ａｃｔｒｉｉ結合性タンパク質及びその使用 Active JP7669291B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025067310A JP2025118664A (ja) 2019-05-30 2025-04-16 Ａｃｔｒｉｉ結合性タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854625P 2019-05-30 2019-05-30
US62/854,625 2019-05-30
PCT/US2020/035148 WO2020243448A1 (en) 2019-05-30 2020-05-29 Actrii-binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025067310A Division JP2025118664A (ja) 2019-05-30 2025-04-16 Ａｃｔｒｉｉ結合性タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2022534966A JP2022534966A (ja) 2022-08-04
JPWO2020243448A5 JPWO2020243448A5 (enExample) 2023-06-06
JP7669291B2 true JP7669291B2 (ja) 2025-04-28

Family

ID=73553540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570756A Active JP7669291B2 (ja) 2019-05-30 2020-05-29 Ａｃｔｒｉｉ結合性タンパク質及びその使用
JP2025067310A Pending JP2025118664A (ja) 2019-05-30 2025-04-16 Ａｃｔｒｉｉ結合性タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025067310A Pending JP2025118664A (ja) 2019-05-30 2025-04-16 Ａｃｔｒｉｉ結合性タンパク質及びその使用

Country Status (8)

Country Link
US (1) US20220242956A1 (enExample)
EP (1) EP3976630A4 (enExample)
JP (2) JP7669291B2 (enExample)
KR (1) KR20220029563A (enExample)
CN (1) CN114127087A (enExample)
AU (1) AU2020284038A1 (enExample)
CA (1) CA3142149A1 (enExample)
WO (1) WO2020243448A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3211515A1 (en) * 2021-03-10 2022-09-15 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
BR112023018283A2 (pt) * 2021-03-10 2023-10-31 Acceleron Pharma Inc Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca
CA3228901A1 (en) * 2021-09-03 2023-03-09 Chris Xiangyang Lu Anti-acvr2a antibodies and uses thereof
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
TW202513591A (zh) * 2023-08-01 2025-04-01 大陸商來凱醫藥科技（上海）有限公司 抗acvr2b抗體及其用途
AR133979A1 (es) * 2023-09-28 2025-11-19 Sixpeaks Bio Ag ANTICUERPOS DIRIGIDOS A ActRIIA Y ActRIIB

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012525128A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
US20130108650A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
WO2014172448A2 (en) 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
JP2019510001A (ja) 2016-02-22 2019-04-11 アクセルロン ファーマ， インコーポレイテッド 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト
JP2019513015A (ja) 2016-03-10 2019-05-23 アクセレロン ファーマ インコーポレーテッド アクチビン２型受容体結合タンパク質及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
GR1007832B (el) * 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
RS61881B1 (sr) * 2015-04-22 2021-06-30 Biogen Ma Inc Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića
PT3600415T (pt) * 2017-03-24 2025-11-24 Novartis Ag Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012525128A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
US20130108650A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
WO2014172448A2 (en) 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
JP2019510001A (ja) 2016-02-22 2019-04-11 アクセルロン ファーマ， インコーポレイテッド 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト
JP2019513015A (ja) 2016-03-10 2019-05-23 アクセレロン ファーマ インコーポレーテッド アクチビン２型受容体結合タンパク質及びその使用

Also Published As

Publication number Publication date
CN114127087A (zh) 2022-03-01
JP2022534966A (ja) 2022-08-04
WO2020243448A1 (en) 2020-12-03
EP3976630A1 (en) 2022-04-06
US20220242956A1 (en) 2022-08-04
KR20220029563A (ko) 2022-03-08
JP2025118664A (ja) 2025-08-13
WO2020243448A8 (en) 2022-05-05
EP3976630A4 (en) 2024-03-20
CA3142149A1 (en) 2020-12-03
AU2020284038A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
JP7469284B2 (ja) アクチビン２型受容体結合タンパク質及びその使用
JP7669291B2 (ja) Ａｃｔｒｉｉ結合性タンパク質及びその使用
JP7103950B2 (ja) Ａｌｋ７結合性タンパク質及びその使用
JP7617036B2 (ja) Ａｌｋ７結合タンパク質及びその使用
JP2021500895A (ja) Ａｌｋ７結合タンパク質およびその使用
HK40003457A (en) Activin type 2 receptor binding proteins and uses thereof
HK40003457B (en) Activin type 2 receptor binding proteins and uses thereof
CN116217731B (zh) Alk7结合蛋白及其用途
HK40003020A (en) Alk7 binding proteins and uses thereof
HK40003020B (en) Alk7 binding proteins and uses thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250416

R150 Certificate of patent or registration of utility model

Ref document number: 7669291

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150